Edition:
United Kingdom

Seres Therapeutics Inc (MCRB.OQ)

MCRB.OQ on NASDAQ Stock Exchange Global Select Market

8.01USD
4:16pm BST
Change (% chg)

$-0.03 (-0.37%)
Prev Close
$8.04
Open
$8.06
Day's High
$8.10
Day's Low
$7.97
Volume
6,437
Avg. Vol
44,905
52-wk High
$17.33
52-wk Low
$6.65

Latest Key Developments (Source: Significant Developments)

Seres Therapeutics Reports Qtrly Loss Per Share $0.68
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Seres Therapeutics Inc ::SERES THERAPEUTICS REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATES.SERES ENDED Q2 WITH APPROXIMATELY $96.1 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS.QTRLY TOTAL REVENUE $4.6 MILLION VERSUS $3 MILLION.QTRLY LOSS PER SHARE $0.68.Q2 EARNINGS PER SHARE VIEW $-0.63, REVENUE VIEW $6.6 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Seres Therapeutics Announces FDA Orphan Drug Designation For SER-287 In Treatment Of Pediatric Ulcerative Colitis
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Seres Therapeutics Inc ::SERES THERAPEUTICS ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR SER-287 IN TREATMENT OF PEDIATRIC ULCERATIVE COLITIS.SERES THERAPEUTICS INC - SER-287 PHASE 1B MICROBIOME DATA ARE EXPECTED IN EARLY 2018.  Full Article

Seres Therapeutics Q3 net loss per share ‍$0.17​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Seres Therapeutics Inc : :Seres Therapeutics reports third quarter 2017 financial results and provides update on operational progress.Seres Therapeutics - ‍positive results from SER-287 phase 1B study in mild-to-moderate ulcerative colitis; co to move program into further development​.Seres therapeutics Inc - ‍in early 2018, co anticipates results from SER-262 phase 1B study in primary C. Difficile infection​.Seres Therapeutics Inc qtrly net loss per share ‍$0.17​.Seres Therapeutics Inc qtrly ‍total revenue $23 million versus $13 million​.  Full Article

Seres Therapeutics announces key findings from SER-109 Phase 2 study analyses
Tuesday, 31 Jan 2017 

Seres Therapeutics Inc : Seres Therapeutics announces key findings from SER-109 Phase 2 study analyses . Seres Therapeutics Inc - FDA discussions are ongoing regarding a new, redesigned clinical study for SER-109 . Seres - misdiagnosis of C. Difficile recurrent infection in some patients, suboptimal dosing contributed to reported SER-109 Phase 2 study outcome . Seres - saw statistically significant increase in richness of commensal spore-forming bacterial species in patients treated with SER-109, versus placebo . Seres Therapeutics Inc says no issues regarding product quality or formulation were identified which would have impacted Phase 2 study results . Seres Therapeutics Inc - also assessed whether SER-109 dose impacted degree of microbiome changes observed . Seres Therapeutics - also conducted thorough and detailed investigation of potential impacts of manufacturing and formulation changes implemented in Phase 2 study .Seres - dose used in SER-109 Phase 2 study may have been suboptimal in certain patients, and may have resulted in a "less robust drug effect".  Full Article

BRIEF-Seres Therapeutics Reports Qtrly Loss Per Share Of $0.69

* SERES THERAPEUTICS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATES